BCRX
BioCryst Pharmaceuticals, Inc.
14.25
+
0.00
0.00%
1 x 14.35
1 x 14.54
bid
ask
11 @ 09:22 AM
14.35+0.10 (0.70%)
Bearish
30
Bullish
77
sentiment
0.00
day range
0.00
7.61
52 week range
19.99
Prev Close14.25
Open0.00
Low0.00
High0.00
Volume0.00
Avg. Volume3.10M
Market Cap2.65B
Inst. Own83.89%
Beta2.20
Short Ratio12.23
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target18.60
50day MA11.44
200day MA12.90
^DJI
Dow Jones Industrial Average
33980.30
05:52 PM
+
0.00
0.00%
^IXIC
NASDAQ Composite
12938.10
05:15 PM
+
0.00
0.00%
^GSPC
S&P 500
4274.04
05:52 PM
+
0.00
0.00%
AAPL
174.07
-0.48 (0.27%)
Apple Inc.
174.55
11 @ 09:22 AM
1 x 174.06
1 x 174.08
+
0.00
0.00%
GOOG
120.59
+0.27 (0.23%)
Alphabet Inc.
120.32
9 @ 09:21 AM
10 x 120.63
8 x 0.00
+
0.00
0.00%
AMZN
142.18
+0.08 (0.06%)
Amazon.com, Inc.
142.10
5 @ 09:22 AM
2 x 142.09
1 x 142.22
+
0.00
0.00%
MSFT
291.66
+0.34 (0.12%)
Microsoft Corporation
291.32
8 @ 09:22 AM
8 x 291.65
8 x 291.75
+
0.00
0.00%
BABA
90.00
+0.23 (0.26%)
Alibaba Group Holding Limited
89.77
26 @ 09:21 AM
29 x 90.26
22 x 90.24
+
0.00
0.00%
NFLX
241.65
+0.50 (0.21%)
Netflix, Inc.
241.15
10 @ 09:21 AM
8 x 241.51
11 x 242.40
+
0.00
0.00%
TSLA
917.20
+5.21 (0.57%)
Tesla, Inc.
911.99
11 @ 09:22 AM
10 x 918.35
11 x 0.00
+
0.00
0.00%
NVDA
183.10
-0.25 (0.14%)
NVIDIA Corporation
183.35
11 @ 09:22 AM
8 x 182.80
14 x 183.40
+
0.00
0.00%
AMD
98.16
-0.11 (0.11%)
Advanced Micro Devices, Inc.
98.27
9 @ 09:22 AM
1 x 98.14
1 x 98.27
+
0.00
0.00%
MU
61.70
+0.08 (0.13%)
Micron Technology, Inc.
61.62
17 @ 09:20 AM
11 x 61.65
22 x 61.74
+
0.00
0.00%
SPY
427.24
+0.59 (0.14%)
SPDR S&P 500 ETF Trust
426.65
10 @ 09:22 AM
8 x 427.25
11 x 426.28
+
0.00
0.00%
TQQQ
37.43
+0.13 (0.35%)
ProShares UltraPro QQQ
37.30
9 @ 09:22 AM
8 x 37.50
9 x 37.43
+
0.00
0.00%
BRK-A
455000.00
-2278.00 (0.50%)
Berkshire Hathaway Inc.
457278.00
11 @ 03:59 PM
10 x 0.00
11 x 464000.00
+
0.00
0.00%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| 2022-08-18 | NDAQ:BCRX | Press Release | BioCryst Pharmaceuticals Inc. | stockhouse.com • |
| Russell Investments Group Ltd. Has $1.31 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
| BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading | investorsobserver.com • |
| Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading | investorsobserver.com • |
| BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia | marketscreener.com • |
| State Board of Administration of Florida Retirement System Sells 13040 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | Blackrock Inc. | 13.99M | 199.32M | 7.52% |
| 2022-06-29 | Vanguard Group, Inc. (The) | 13.81M | 196.79M | 7.43% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 181.13M | 6.84% |
| 2022-03-30 | State Street Corporation | 7.46M | 106.34M | 4.01% |
| 2022-06-29 | Pictet Asset Management SA | 6.05M | 86.17M | 3.25% |
| 2022-06-29 | Fisher Asset Management, LLC | 5.22M | 74.34M | 2.81% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 7.26M | 103.50M | 3.91% |
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 74.97M | 2.83% |
| 2022-06-29 | iShares Russell 2000 ETF | 4.17M | 59.43M | 2.25% |
| 2022-05-30 | Fidelity Select Portfolios - Biotechnology | 4.19M | 59.74M | 2.25% |
| 2022-04-29 | Lord Abbett Developing Growth Fund | 2.45M | 34.94M | 1.32% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 34.03M | 1.29% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Cannot wait to get to my average price and Exit this one. The financial news is not bright and the writing is in the wall.
-
Usbanking news. Zach analysts - $0.28 eps Hope it’s incorrect
-
Toilet Stock. More money will bleed out on Monday. That’s all it ever does. It is not a Covid stock. For myself, huge mistake.
-
Please someone explain the sudden change in volume, in layman’s terms, Tysm
-
Please can someone explain the volume? I’m a newer trader. In layman’s terms. Tysm
-
Meant to say write. I misspelled because I’m so upset.
-
Write. Sorry. I can spell. Lol.
-
I am not a big time investor. I’m stuck in this pos stock. I’m now convinced more then ever this Company is Shady. I had 30 shares limit buy at 3.95. I saw it drop to pick it up then right back up. I don’t know much but I’m convinced this is rigged. It’s doing it again as I right this. Dipping down sudden then back up.
-
It’s going nowhere.
-
Any year now. Maybe 2022 will be the year
-
If Gladisvir was even possibly going to be a contender in Covid wouldn’t there be some shred of news out on that lately? I hope the positive hopes are correct but it feels like grasping at straws at this point. This stock needs to S—- or get off the pot. There’s just crickets on BCRX.
-
It just keeps getting better and better. Nightmare stock
-
Shady Shady something is not right here. Controlled stock. Live and learn. First dilution then you notice the pattern.
-
Manipulated stock. Want out. Waste of time.
-
Let’s be honest this stock is broken. NG
-
Same volume same price range day in and day out. Like watching paint dry
-
Why doesn’t this stock ever move? If I was even ,I’d get out and buy back later. It just shows no signs of life. -
It’s just stuck! Zzzzz
-
Re Dexamethasone is all you need, that news states it’s for severe cases and patients are already vented. The key would be meds that treat you before you get to that point.
-
@Vafa sorry my words connected. Can’t find edit here.
-
BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading
investorsobserver.com • -
Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading
investorsobserver.com • -
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
marketscreener.com • -
Top 5 2nd Quarter Trades of Biondo Investment Advisors, LLC
gurufocus.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •
